Khushi Verma1, Rajesh Kumar Nema¹*, Harish Sharma² and Gyanesh Kumar Sahu¹

¹Rungta Institute of Pharmaceutical Sciences, Kohka (C.G), India
²Rungta Institute of Pharmaceutical Sciences and Research, Kohka (C.G), India

*Corresponding Author: Rajesh Kumar Nema, Principal, Rungta Institute of Pharmaceutical Sciences, Kohka (C.G), India.

Received: April 08, 2024; Published: May 02, 2024

Abstract

Eye diseases are commonly encountered in day-to-day life, which are cured or prevented through the conventionally used dosage forms like eye drops, ointments. Delivery to the internal parts of the eye still remains troublesome due to the anatomical and protective structure of the eye. The newly developed particulate and vesicular systems like liposomes, pharmacosomes and discomes are useful in delivering the drug for a longer extent and helpful in reaching the systemic circulation. The most recent advancements of the ocular delivery systems provide the delivery of the genes and proteins to the internal structures which were once inaccessible and thus are of great importance in treating the diseases which are caused due to genetic mutation, failure in normal homeostasis, malignancy but also maintaining the physiological function of eye. The review focuses on the developments achieved in this mode of delivery of the drugs along with the pros and cons associated with greater focus on the advanced delivery systems.

Keywords: Advance Ocular Therapy, Control Drug Delivery Systems, Corneal Permeability, Iontophoresis; Eye; Hydrogel

References

1. Hughes PM and Mitra “Overview of ocular drug delivery and iatrogenic ocular cytopathologies”. In: Mitra AK. Ophthalmic Drug Delivery Systems. 2^nd edition. New York: M. Dekker Inc (1993): 1-27.
2. Bourlais CL., et al. “Ophthalmic drug delivery systems- recent advances”. Progress in Retinal and Eye Research 17 (1988): 33-58.
3. Kaur IP., et al. “Vesicular systems in ocular drug delivery: an overview”. International Journal of Pharmaceutics 269 (2004): 1-14.
4. Wadhwa S., et al. “Nanocarriers in ocular drug delivery: An update review”. Current Pharmaceutical Design 15 (2009): 2724-2750.
5. Mueller WH and Deardroff DL. “Ophthalmic vehicles: The effect of methyl cellulose on the penetration of Homatropine hydro bromide through the cornea”. Journal of the American Pharmacists Association 45 (1956): 334-341.
6. Urtti A., et al. “Controlled drug delivery devices for experimental ocular studies with timolol, Ocular and systemic absorption in rabbits”. International Journal of Pharmaceutics 61 (1990): 241-249.
7. Geroski DH and Edelhauser “Drug delivery for posterior segment eye diseases”. Investigative Ophthalmology and Visual Science 41 (2000): 961-964.
8. Sultana Y., et al. “Review of Ocular Drug Delivery”. Current Drug Delivery 3 (2006): 207-217.
9. Mishra DN and Gilhotra “Design and characterization of bioadhesive in-situ gelling ocular insert of gatifloxacin sesquihydrate”. DARU 16 (2008): 1-8.
10. Lawrenson JG., et al. “Comparison of the efficacy and duration of action of topically applied proxymetacaine using a novel ophthalamic delivery system versus eye drops in healthy young volunteers”. British Journal of Ophthalmology 77 (1993): 713-715.
11. Ebrahim S., et al. “Applications of liposomes in ophthalmology”. Survey of Ophthalmology 50 (2005): 167-182.
12. Kaur IP., et al. “Vesicular systems in ocular drug delivery: An overview”. International Journal of Pharmaceutics 269 (2004): 1-14.
13. Shek PN and Barber RF. “Liposomes are effective carriers for the ocular delivery of prophylactics”. Biochimica et Biophysica Acta 902 (1987): 229-236.
14. Vyas SP., et al. “Discoidal niosome based controlled ocular delivery of timolol maleate”. Pharmazie7 (1998): 466-469.
15. FF Behar-Cohen., et al. “Transscleral Coulombcontrolled iontophoresis of methyl prednisolone into the rabbit eye: Influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels”. Experimental Eye Research1 (2002A): 51-59.
16. BC Hayden., et al. “Pharmacokinetics of systemic versus focal carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of retinoblastoma”. Investigative Ophthalmology and Visual Science 45 (2009): 3644-3649.
17. M Voigt., et al. “Ocular aspirin distribution: a comparison of intravenous, topical, and coulomb-controlled iontophoresis administration”. Investigative Ophthalmology and Visual Science10 (2002): 3299-3306.
18. RF Jones and DM Maurice. “New methods of measuring the rate of aqueous flow in man with fluorescein”. Experimental Eye Research 5 (1966): 208-220.
19. R Grossman., et al. “Regional ocular gentamicin levels after transcorneal and transscleral iontophoresis”. Investigative Ophthalmology and Visual Science 31 (1990): 909-916.
20. J Frucht-Pery., et al. “The distribution of gentamicin in the rabbit cornea following iontophoresis to the central cornea”. Journal of Ocular Pharmacology and Therapeutics3 (1999): 251-256.
21. J Frucht-Pery., et al. “Efficacy of iontophoresis in the rat cornea”. Graefe’s Archive for Clinical and Experimental Ophthalmology 234 (1996): 765-769.
22. GA Fischer., et al. “OcuPhor-the future of ocular drug delivery”. Drug Delivery Technology 2 (2002): 50-52.
23. TM Parkinson., et al. “Tolerance of ocular iontophoresis in healthy volunteers”. Journal of Ocular Pharmacology and Therapeutics2 (2003): 145-151.
24. TM Parkinson., et al. “The effects of in vivo iontophoresis on rabbit eye structure and retinal function”. Investigative Ophthalmology and Visual Science 41 (2000): S772
25. DL Vollmer., et al. “In vivo transscleral iontophores is of amikacin to rabbit eyes”. Journal of Ocular Pharmacology and Therapeutics 6 (2002): 549-558.
26. MS Hastings., et al. “Visulex: advancing iontophoresis for effective noninvasive back-to-the-eye therapeutics”. Drug Delivery Technology 3 (2004): 53-57.
27. E Eljarrat-Binstock., et al. “Transcorneal and transscleral iontophoresis of dexamethasone phosphate in rabbits using drug loaded hydrogel”. Journal of Controlled Release3 (2005): 386-390.
28. E Eljarrat-Binstock., et al. “Hydrogel probe for iontophoresis drug delivery to the eye”. Journal of Biomaterials Science. Polymer Edition 4 (2004): 397-413.
29. E Eljarrat-Binstock., et al. “Delivery of gentamicin to the rabbit eye by drug-loaded hydrogel iontophoresis”. Investigative Ophthalmology and Visual Science8 (2004): 2543-2548.
30. J Frucht-Pery., et al. “Iontophoresisgentamicin delivery into the rabbit cornea, using a hydrogel delivery probe”. Experimental Eye Research3 (2004): 745-749.
31. F Brouneus., et al. “Diffusive transport properties of some local anesthetics applicable for iontophoretic formulation of the drugs”. International Journal of Pharmaceutics1-2 (2001): 57-62.
32. CR Anderson., et al. “Effects of iontophoresis current magnitude and duration on dexamethasone deposition and localized drug retention”. Physical Therapy2 (2003): 161-170.
33. SS Kamath and LP Gangarosa. “Electrophoretic evaluation of the mobility of drugs suitable for iontophoresis”. Methods and Findings in Experimental and Clinical Pharmacology4 (1995): 227-232.
34. D Monti., et al. “Effect of iontophoresis on transcorneal permeation Fin vitro_ of two beta-blocking agents, and on corneal hydration”. International Journal of Pharmaceutics2 (2003): 423-429.
35. O Camber., et al. “Permeability of prostaglandin F2 and prostaglandin F2 esters across cornea in vitro”. International Journal of Pharmaceutics 29 (1986): 259-266.
36. PH Fishman., et al. “Iontophoresis of gentamicin into aphasic rabbit eyes”. Investigative Ophthalmology and Visual Science 25 (1984): 343-345.
37. TB Choi and DA Lee. “Transscleral and transcorneal iontophoresis of vancomycin in rabbit eyes”. Journal of Ocular Pharmacology 2 (1988): 153-164.
38. DS Rootman., et al. “Pharmacokinetics and safety of transcorneal iontophoresis of tobramycin in the rabbit”. Investigative Ophthalmology and Visual Science9 (1988): 1397-1401.
39. J Frucht-Pery., et al. “Iontophoretic treatment of experimental pseudomonas keratitis in rabbit eye using gentamicinloaded hydrogel, (submitted for publication) (2009).
40. Fujiwara T., et al. “Enhanced depth imaging optical coherence tomography of the choroid in highly myopic eyes”. American Journal of Ophthalmology 148 (2009): 445-450.
41. Ramrattan RS., et al. “Morphometric analysis of Bruch’s membrane, the choriocapillaris, and the choroid in aging”. Investigative Ophthalmology and Visual Science 35 (1994): 2857-2864.
42. Spraul CW., et al. “Histologic and morphometric analysis of the choroid, Bruch’s membrane, and retinal pigment epithelium in postmortem eyes with age-related macular degeneration and histologic examination of surgically excised choroidal neovascular membranes”. Survey of Ophthalmology 1 (1999): S10-32.
43. Hewitt AT and Newsome DA. “Altered synthesis of Bruch’s membrane proteoglycans associated with dominant retinitis pigmentosa”. Current Eye Research 4 (1985): 169-174.
44. Hewitt AT., et al. “Analysis of newly synthesized Bruch’s membrane proteoglycans”. Investigative Ophthalmology and Visual Science 30 (1989): 478-486.
45. Farboud B., et al. “Development of a polyclonal antibody with broad epitope specificity for advanced glycation end products and localization of these epitopes in Bruch’s membrane of the aging eye”. Molecular Vision 5 (1999):
46. Handa JT., et al. “Increase in the advanced glycation end product pentosidine in Bruch’s membrane with age”. Investigative Ophthalmology and Visual Science 40 (1999): 775-779.
47. Yamada Y., et al. “The expression of advanced glycation endproduct receptors in rpe cells associated with basal deposits in human maculas”. Experimental Eye Research 82 (2006): 840-848.
48. Candiello J., et al. “Biomechanical properties of native basement membranes”. FEBS Journal 274 (2007): 2897-2908.
49. Mordenti J., et al. “Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration”. Toxicologic Pathology 27 (1999): 536-544.
50. Heiduschka P., et al. “The tubingen Bevacizumab study, G. penetration of Bevacizumab through the retina after intravitreal injection in the monkey”. Investigative Ophthalmology and Visual Science 48 (2007): 2814-2823.
51. Dib E., et al. “Subretinal bevacizumab detection after intravitreous injection in rabbits”. Investigative Ophthalmology and Visual Science 49 (2008): 1097-1100.
52. Sakurai E., et al. “Effect of particle size of polymeric nanospheres on intravitreal kinetics”. Ophthalmic Research 33 (2001): 31-36.
53. Bourges JL., et al. “Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles”. Investigative Ophthalmology and Visual Science 44 (2003): 3562-3569.
54. Cunha-Vaz J. “The blood-ocular barriers”. Survey of Ophthalmology 23 (1979): 279-296.
55. Schnitzer JE., et al. “Endothelial caveolae have the molecular transport machinery for vesicle budding, docking, and fusion including VAMP, NSF, SNAP, annexins, and GTPases”. Journal of Biological Chemistry 270 (1995): 14399-14404.
56. Simionescu M., et al. “Transcytosis of plasma macromolecules in endothelial cells: A cell biological survey”. Microscopy Research and Technique 57 (2002): 269-288.
57. Hosny KM. “Ciprofloxacin as ocular liposomal hydrogel”. AAPS PharmSciTech 11 (2010): 241-246.
58. Zhang J., et al. “Freezedried liposomes as potential carriers for ocular administration of cytochrome c against selenite cataract formation”. Journal of Pharmacy and Pharmacology 61 (2009): 1171-1178.
59. Zhang J and Wang S. “Topical use of coenzyme Q10-loaded liposomes coated with trimethyl chitosan: Tolerance, precorneal retention and anti-cataract effect”. International Journal of Pharmaceutics 372 (2009): 66-75.
60. Aggarwal D and Kaur IP. “Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system”. International Journal of Pharmaceutics 290 (2005): 155-159.
61. Kaur IP., et al. “Improved ocular absorption kinetics of timolol maleate loaded into a bioadhesive niosomal delivery system”. Graefe's Archive for Clinical and Experimental Ophthalmology 248 (2010): 1467-1472.
62. Guinedi AS., et al. “Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide”. International Journal of Pharmaceutics 306 (2005): 71-82.
63. Aggarwal D., et al. “Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor”. International Journal of Pharmaceutics 338 (2007): 21-26.
64. Abdelbary G and El-Gendy N. “Niosome-encapsulated gentamicin for ophthalmic controlled delivery”. AAPS PharmSciTech 9 (2008): 740-747.
65. Garg G., et al. “Cubosomes: An overview”. Biological and Pharmaceutical Bulletin 30 (2007): 350-353.
66. Gan L., et al. “Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability”. International Journal of Pharmaceutics 396 (2010): 179-187.
67. Han S., et al. “Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability”. Acta Pharmacologica Sinica 31 (2010): 990-998.
68. Klang SH., et al. “Evaluation of a positively charged submicron emulsion of piroxicam on the rabbit corneum healing process following alkali burn”. Journal of Controlled Release 57 (1999): 19-27.
69. Abdulrazik M., et al. “Ocular delivery of cyclosporin A. II. Effect of submicron emulsion’s surface charge on ocular distribution of topical cyclosporin A”. Paris: Editions de sante (2001).

Citation

Citation: Rajesh Kumar Nema., et al. “Advances and Challenges in Ocular Drug Delivery Systems: A Comprehensive Review".Acta Scientific Pharmaceutical Sciences 8.6 (2024): 03-16.

Copyright

Copyright: © 2024 Rajesh Kumar Nema., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.